Nitromed's BiDil Could Be First Drug Approved Specifically For African Americans
This article was originally published in The Pink Sheet Daily
Executive Summary
Company plans NDA resubmission by year-end with results from African American Heart Failure Trial in response to 2001 "approvable" letter for treatment of heart failure in African American patients. A-HeFT data show 43% survival improvement with BiDil vs. placebo.